ChengDu ShengNuo Biotec (688117) Fundamentals 2026 — P/E 20.5x, Revenue Analysis | SniperIQ
ChengDu ShengNuo Biotec (688117) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥5.3B, trading at ¥24.00 on the SHH. This SniperIQ fundamentals page covers ChengDu ShengNuo Biotec's valuation (P/E 20.5x, P/B 3.4x), profitability (net margin 23.1%), revenue (¥741M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is ChengDu ShengNuo Biotec's market cap?
ChengDu ShengNuo Biotec (688117) has a market capitalization of approximately ¥5.3B, trading at ¥24.00 on the SHH. Market cap moves with the live share price.
What is ChengDu ShengNuo Biotec's P/E ratio?
ChengDu ShengNuo Biotec's trailing twelve-month P/E ratio is 20.5x, with a price-to-book (P/B) of 3.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is ChengDu ShengNuo Biotec?
ChengDu ShengNuo Biotec runs a net profit margin of 23.1%, a gross margin of 97.9%, and an operating margin of 28.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does ChengDu ShengNuo Biotec generate?
ChengDu ShengNuo Biotec reported revenue of ¥741M for fiscal year 2025, with net income of ¥158M and earnings per share (EPS) of 1. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does ChengDu ShengNuo Biotec pay a dividend?
ChengDu ShengNuo Biotec offers a trailing dividend yield of about 1.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is ChengDu ShengNuo Biotec financially healthy?
ChengDu ShengNuo Biotec carries a debt-to-equity ratio of 0.44x and a current ratio of 2.12x, with a market beta of 0.57. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is ChengDu ShengNuo Biotec a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For ChengDu ShengNuo Biotec (688117) the key facts are: market cap ¥5.3B, P/E 20.5x, revenue ¥741M, 52-week range 20.91-34.26429. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track ChengDu ShengNuo Biotec's full fundamentals live
Get ChengDu ShengNuo Biotec's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.